Bhagavatheeswaran, Prabhu
Memorial Sloan Kettering Cancer Center · Spanish National Cancer Research Centre · Bristol-Myers Squibb (United States) · Institut Català d'Oncologia · Hospital Universitario Virgen del Rocío · Centro de Investigación Biomédica en Red de Cáncer
3 papers on CoChat
Most cited papers
- Verified
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 3,063
- Verified
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 2,823
- Verified
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 2,503
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free